Login to Your Account

Other News To Note

Thursday, December 15, 2011

• NeurOp Inc., of Atlanta, said New York-based Bristol-Myers Squibb Co. agreed to fund an additional year of research for NeurOp's small molecules in major depression and neuropathic pain. The funding extension continues the firms' 2009 agreement, under which BMS paid a $1.5 million licensing fee and NeurOp could receive up to $74 million in milestone payments and royalties.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription